Comprehensive Analysis of Relapse in Multiple Sclerosis
Comprehensive Analysis of Relapse in Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Corticotropin
Melanocortin receptor 2 agonist
What it measured
Main measures
Changes in immunorepertoire, MRI imaging, clinical outcomes and patient reported quality of life
within 1 month post initiation of treatment with Acthar Gel
RelapsesMRI lesionsQuality of life (reported by participants)Immune response
Who could take part
Relapsing MS · 19 to 65
Show the full criteria
Inclusion criteria
* Patients will be eligible to participate in the study if: They were diagnosed with Relapsing-Remitting Multiple Sclerosis within 1 year of their participation in the study Are established patients of the Tanner Center for MS Seek care for relapse within 72 hours of onset Are between the ages of 19 and 65 inclusively. Relapse will be confirmed and defined as the acute worsening of function that lasts for at least 24 hours with any of the manifestations of Central Nervous System relapses (excluding spinal cord) including: Brain stem syndrome Optic neuritis Cerebellar syndromes Hemi-motor/sensory events Males and Females are both eligible Patients of any race or ethnicity are eligible Are not pregnant (as confirmed by pregnancy test at the time of enrollment) or nursing Have no known contraindicating conditions (see exclusions)
Exclusion criteria
* Potential participants will be excluded if they do not meet the above criteria, and also if: They are currently being treated for MS with the any of the following disease-modifying drugs: Tysabri, Gilenya, Aubagio, Tecfidera They have a history of experiencing significant adverse reactions to corticosteroids They are deemed by Dr Riser to be better served with an intervention other than Acthar Gel to treat their current MS relapse Are pregnant or nursing Are known to have any of the contraindicating conditions: Scleroderm Osteoporosis Systemic fungal infections Ocular herpes simplex Recent surgery History of or presence of peptic ulcer Congestive heart failure Uncontrolled hypertension Adreno-cortical insufficiency, hyper-function or sensitivity Sensitivity to proteins of porcine origin
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study will determine changes in: 1) the immune activity, characterized as the "immunorepertoire;" 2) 7 Tesla MRI brain images; 3) clinical outcomes; and 4) patient reported quality of life outcomes in subjects with relapsing-remitting multiple sclerosis who are treated with Acthar Gel.
Loading reviews and guidelines…
Related trials
- Improving the Treatment of Acute Relapses in Multiple Sclerosis Throug
Phase 2 · Enrolling by invitation
Still running
- Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in
Phase 2 · Completed
No results found
- Methylprednisolone During the Switch Between Natalizumab and Fingolimo
Phase 4 · Status unknown
No results found
- Maximizing Outcome of Multiple Sclerosis Transplantation
Phase 3 · Stopped early
Stopped
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab
Phase 3 · Stopped early
Stopped
- Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse
Phase 4 · Stopped early
Stopped: safety
History
Started
Aug 2013
Main results due
Jan 2014
Finished
Jan 2015